Table 2.
PG subjects (n = 1674) |
Non-PG subjects (n = 1275) |
P | |
---|---|---|---|
cEVR, n (%) | 696 (42) | 493 (39) | 0.11 |
SVR, n (%) | 683 (41) | 485 (38) | 0.13 |
EOT, n (%) | 938 (56) | 705 (55) | 0.69 |
Relapse, n (%) | 215/886 (24) | 180/661 (27) | * |
Discontinuation for AE, n (%) | 196 (12) | 151 (12) | 0.91 |
SAE, n (%) | 164 (10) | 128 (10) | 0.83 |
12-week PEG adherence> 80%, n (%) | 1527 (91) | 1141 (89) | 0.11 |
12-week RBV adherence> 80%, n (%) | 1485 (89) | 1144 (90) | 0.38 |
Not tested since denominator for comparison groups (EOT responder) is not based on factor determined at randomization.
Abbreviations: cEVR, complete early virological response; PG, pharmacogenomics; SVR, sustained virological response; EOT, end of treatment response; AE, adverse event; SAE, serious adverse event; PEG, pegylated interferon-alfa; RBV, ribavirin.